Actionable biological programs to enhance EGFR-targeted therapy response unveiled by single-cell lineage tracing in clinically relevant lung cancer models

Beatrice Gini, Whitney Tamaki, Johnny Yu, Dora Barbosa, Wei Wu, Yashar K. Pourmoghadam, Paul Allegakoen, Donghwa Kim, Sohit Miglani, Sarah Elmes, Victor Olivas, Hani Goodarzi, Trever G. BivonabioRxiv 2025 · DOI

TL;DR

This study introduces a novel single-cell lineage tracing approach to track how lung cancer cells evolve under EGFR-targeted therapy. They discovered pre-existing "seeds" of resistant cells within tumors, characterized by specific gene expression programs (Hedgehog and FOXD1 pathways), which allow them to survive and proliferate despite treatment. This work paves the way for identifying and targeting these resistant populations to improve therapeutic outcomes.

What Problem Does This Paper Address?

Lung cancer, particularly EGFR-mutant non-small cell lung cancer (NSCLC), often develops resistance to targeted therapies like osimertinib, leading to treatment failure and disease progression. While we know that tumors are heterogeneous and can adapt, understanding the specific evolutionary trajectories of individual cancer cell lineages under drug pressure has been challenging. Traditional methods often lack the resolution to track these subtle changes or identify the early warning signs of resistance. This paper aims to bridge this gap by developing and applying a high-resolution lineage tracing method to uncover the molecular mechanisms and cellular origins of drug resistance in NSCLC.

Methods

The core innovation here is a static barcoding approach combined with single-cell RNA sequencing (scRNA-seq). Here's how it works:

  • Lentiviral Barcoding: Cancer cells (patient-derived organoids - PDOs, and xenografts - CDXs) are engineered to carry unique, stable genetic "barcodes." These barcodes act like unique identifiers for each cell and its progeny.
  • Lineage Tracing: Over time and under drug treatment, these barcodes allow researchers to track the expansion and evolution of specific cell lineages.
  • Single-Cell RNA Sequencing (scRNA-seq): Simultaneously, scRNA-seq is performed on these barcoded cells. This provides a snapshot of the gene expression profile (transcriptome) of each individual cell.
  • Integration: By linking the genomic barcode (lineage information) with the scRNA-seq data (transcriptional state), the researchers can identify which lineages are expanding and what transcriptional programs they are employing.
  • Pathway Analysis (iPAGE): This tool is used to identify enriched biological pathways within specific lineages, helping to understand the functional adaptations occurring.

This combination is powerful because it allows researchers to see which cells are surviving and how they are changing their gene expression to do so, all within a complex, clinically relevant model.

Datasets

The study utilized:

  • Primary EGFR-mutant NSCLC Patient-Derived Organoids (PDOs): These are 3D cultures derived from patient tumors, offering a more biologically relevant model than simple cell lines.
  • EGFR-mutant NSCLC Xenografts (CDXs): These are tumors grown in immunocompromised mice from human NSCLC cells, providing an in vivo model.
  • Clinical Datasets: Single-cell RNA sequencing data from human EGFR-mutant NSCLC patient tumors (treatment-naïve and residual disease) were used for validation.

Key Insights and Ideas

  • Pre-existing "Seeds" of Resistance: The most striking finding is that resistance isn't always acquired de novo. Instead, there appear to be pre-existing, rare cell populations within the tumor that are already primed for resistance. These "seeds" are selected and expand under drug pressure.
  • Hedgehog and FOXD1 Pathways as Resistance Drivers: These pre-existing resistant lineages are characterized by the upregulation of specific transcriptional programs, notably the Hedgehog (Hh) signaling pathway and the FOXD1 regulon. This suggests these pathways play a crucial role in conferring resistance to EGFR inhibitors.
  • Lineage Tracing Uncovers "Hidden" Populations: Standard scRNA-seq might miss these rare, pre-existing resistant lineages because they are not dominant before treatment. The barcoding lineage tracing approach is essential for their detection and characterization.
  • Plasticity and Adaptation: The study highlights how these resistant lineages can undergo transcriptional rewiring, including transitioning towards an Epithelial-Mesenchymal Transition (EMT) phenotype, to further enhance their survival and persistence.
  • Therapeutic Vulnerability: By identifying these specific pathways (Hh and FOXD1) and the cells that express them, the research opens up possibilities for combination therapies that target these resistance mechanisms.

Key Results

  • Identification of Two Key Resistant Lineages: In both PDOs and xenografts, the researchers identified specific lineages that became dominant under osimertinib treatment.
  • Hedgehog Pathway Upregulation in Resistant PDO Lineages: Pre-treatment analysis of resistant PDO lineages (L.D) revealed enrichment of Hallmark Hedgehog Signaling pathway genes.
  • FOXD1 Regulon in Resistant Xenograft Lineages: In xenografts, lineage A, which showed a stable transcriptional signature and increased frequency under osimertinib, was characterized by a pre-existing FOXD1 regulon.
  • Combination Therapy Efficacy: Pharmacological inhibition of the Hedgehog pathway in combination with osimertinib significantly enhanced sensitivity and reduced organoid formation compared to monotherapy. This combination also suppressed EMT markers.
  • FOXD1 Knockdown Increases Sensitivity: Knocking down FOXD1 in resistant xenograft cells (L.A) significantly reduced their colony formation in the presence of osimertinib, confirming its role in resistance.
  • Clinical Validation: Analysis of clinical NSCLC data showed that Hedgehog signaling and FOXD1 regulon expression were indeed higher in treatment-naïve tumors compared to residual disease, supporting the idea of pre-existing resistance programs.

Limitations and Future Work

  • Model Systems: While PDOs and CDXs are valuable, they are still preclinical models and may not perfectly recapitulate the complexity of human tumors in vivo.
  • Functional Characterization of NR4A1: The paper identifies NR4A1 as a key gene within the FOXD1 regulon and hypothesizes its role in resistance. However, its precise functional role in EGFR inhibitor resistance requires further investigation.
  • Translational Potential: The authors suggest that identifying and targeting plasticity-primed states is a promising avenue. Future work will focus on translating these findings into clinical strategies, such as developing combination therapies that target the Hh and FOXD1 pathways in conjunction with EGFR inhibitors. This could lead to better prediction of treatment response and more durable therapeutic outcomes for NSCLC patients.

Summary updated

Abstract

Abstract Developing high-resolution approaches to capture both tumor architectural clonality and transcriptional state(s) in individual cells within heterogeneous tumor cell populations could shed light on the evolution of pre-existing and newly emergent tumor subclones and their phenotypes, elucidating their trajectories in response to selective pressures such as drug treatment. Reports to date have focused primarily on analyzing the drug-induced evolution of lung cancer cells in in vitro preclinical models with limited complexity and a relative lack of characterization of actionable biological programs to induce durable responses. Here, we challenged this paradigm and employed a lineage tracing single-cell RNAseq method to track the evolution of primary non-small cell lung cancer (NSCLC) patient-derived organoids (PDOs) and tumor xenografts in response to the standard-of-care EGFR inhibitor osimertinib, with a focus on understanding drug persistence and resistance. Our single-cell lineage tracing-RNAseq system revealed the presence of a discrete set of lineages with distinct transcriptional phenotypes over the course of the treatment. We identified two lineage populations that became predominant during drug treatment and resisted therapy in the PDOs and tumor xenografts. These lineages were present before treatment and harbored Hedgehog pathway and FOXD1 transcriptional programs, respectively. These specific transcriptomic lineages were otherwise undetectable by lower-resolution profiling. Functional studies confirmed the protective role that the baseline expression of the Hedgehog pathway and FOXD1 programs in the lineage tumor cell sub-populations exerts upon targeted therapy. The potential clinical relevance of these regulatory programs was validated by cross-analysis of single-cell transcriptomic data obtained from human NSCLC specimens. Overall, our approach identified pre-existing seeds of resistance before therapy and convergent, adaptive mechanisms supporting tumor residual disease and resistant states. This study highlights the utility of high-resolution tracing of tumor clonal heterogeneity with matched single-cell profiling to reveal occult cell states and molecular mechanisms of therapy resistance and develop counteracting strategies.
BibTeX
@misc{gini2025actionable,
  author = {Beatrice Gini and Whitney Tamaki and Johnny Yu and Dora Barbosa and Wei Wu and Yashar K. Pourmoghadam and Paul Allegakoen and Donghwa Kim and Sohit Miglani and Sarah Elmes and Victor Olivas and Hani Goodarzi and Trever G. Bivona},
  title = {{Actionable biological programs to enhance EGFR-targeted therapy response unveiled by single-cell lineage tracing in clinically relevant lung cancer models}},
  year = {2025},
  doi = {10.1101/2025.05.19.654081},
  howpublished = {bioRxiv},
}
Figure